Myriad Genetics (MYGN) Beat But Not By Enough, Mizuho Says; PT to $34
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Wall St slides as oil tops $100, yields hit 2023 high; Apple down before Ternus' first launch event as CEO
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Oil nears $100 as fresh Middle East strikes raise supply risks
- How big a risk are rates to the AI boom?
- 3 reasons why S&P 500 may drop up to 10% in the near term: RBC
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Leerink Partners Remains Sidelined on Myriad Genetics (MYGN) - PT to $41
May 4, 2016 7:44 AM EDTLeerink Partners maintained a Market Perform rating on Myriad Genetics (NASDAQ: MYGN), and cut the price target to $41.00 (from $44.00), following the company's 3Q earnings report. MYGN reported revenue of $190.5M, beating expectations of $185M by ~3%. Management guided F4Q revenue in the... More
Myriad Genetics (MYGN) Tops Q3 EPS by 3c, Offers Q4 & FY Guidance
May 3, 2016 4:07 PM EDTMyriad Genetics (NASDAQ: MYGN) reported Q3 EPS of $0.41, $0.03 better than the analyst estimate of $0.38. Revenue for the quarter came in at $190.5 million versus the consensus estimate of $184.92 million.
GUIDANCE:
Myriad Genetics sees Q4 2016 EPS of $0.36-$0.38, versus the consensus of... More
